Pyxis taking scalpel to preclinical pipeline, stops development on half — for now
A Cambridge, MA biotech is looking to push to the clinic, and it’s willing to throw other candidates to the wayside.
Pyxis Oncology put out word Monday morning in its Q2 earnings release that the company is shifting its short-term emphasis — focusing on two programs and either pausing or ceasing work on three more.
“We have elected to sharpen our near-term focus on the clinical execution of our two most advanced programs, anti-EDB Antibody Drug Conjugate (ADC), PYX-201, and anti-Siglec-15 monoclonal antibody (mAb), PYX-106,” CEO Lara Sullivan said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.